Scarica l'app Stockscreener
6.05
1.51%
0.09
Dopo l'orario di chiusura:
6.07
0.02
+0.33%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$5.96
Aprire:
$6
Volume 24 ore:
3.63M
Relative Volume:
0.73
Capitalizzazione di mercato:
$1.86B
Reddito:
$493.67M
Utile/perdita netta:
$-104.69M
Rapporto P/E:
-17.79
EPS:
-0.34
Flusso di cassa netto:
$-31.51M
1 W Prestazione:
-3.04%
1M Prestazione:
+7.27%
6M Prestazione:
-36.38%
1 anno Prestazione:
-41.71%
Intervallo 1D:
$5.95
$6.12
Intervallo di 1 settimana:
$5.88
$6.77
Portata 52W:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Confronta FOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
6.05 | 1.92B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
What drives Amicus Therapeutics Inc. stock priceTremendous return rates - Autocar Professional
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 - GlobeNewswire
Amicus Therapeutics Sets Date for Q2 Earnings: Key Updates Expected from Rare Disease Pipeline - Stock Titan
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Upgraded by Morgan Stanley - MarketBeat
Is Amicus Therapeutics Inc. a good long term investmentRemarkable growth - PrintWeekIndia
58,396 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Purchased by Edgestream Partners L.P. - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpWhat's Next? - MarketBeat
Amicus Therapeutics Inc. Stock Analysis and ForecastFree Stock Market Forecast Reports - jammulinksnews.com
What analysts say about Amicus Therapeutics Inc. stockDouble-digit growth - jammulinksnews.com
Amicus (FOLD) Gets Japan Approval for Pombiliti + Opfolda - MSN
Amicus gains as Morgan Stanley upgrades on Aurobindo case and Pom-Op switching - MSN
Amicus stock gains as Morgan Stanley upgrades (FOLD:NASDAQ) - Seeking Alpha
Amicus Therapeutics (FOLD) Soars 10.05% on Japan Approval - AInvest
Rice Hall James & Associates LLC Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics stock upgraded to Overweight by Morgan Stanley on IP strength - Investing.com Canada
Stephens Investment Management Group LLC Makes New $5 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
10 Best Small-Cap Stocks to Buy According to Billionaires - Insider Monkey
Q2 EPS Estimate for Amicus Therapeutics Increased by Analyst - MarketBeat
Zacks Research Issues Optimistic Forecast for FOLD Earnings - MarketBeat
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $16.22 - MarketBeat
Amicus Therapeutics (FOLD): Securing Rare Disease Dominance Through Strategic Deals and Pipeline Momentum - AInvest
TD Cowen Remains Bullish on Amicus Therapeutics (FOLD) With a $20 PT - Yahoo Finance
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm - WV News
Amicus Therapeutics (FOLD) Announces Approval for Pombiliti + Opfolda by Japan’s Ministry of Health, Labour and Welfare (MHLW) - MSN
(FOLD) Investment Report - news.stocktradersdaily.com
High Growth Tech Stocks In The US To Watch This July 2025 - simplywall.st
Amicus Therapeutics (NASDAQ:FOLD) Sets New 12-Month LowWhat's Next? - MarketBeat
Amicus (FOLD) Gains Approval for Pompe Disease Treatment in Japan | FOLD Stock News - GuruFocus
Amicus announces approval of Pombiliti + Opfolda in Japan - TipRanks
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan - GlobeNewswire
Breakthrough: Japan Approves Amicus' Novel Treatment for Late-Onset Pompe Disease Patients - Stock Titan
Amicus Therapeutics Publishes Positive PROPEL Study Data for Pompe Disease Treatment - Yahoo.co
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):